Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer

NCT07027124 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer
High-risk Prostate Cancer

Interventions

DRUG: Darolutamide
DRUG: Pembrolizumab
DRUG: Lupron

Sponsor

Icahn School of Medicine at Mount Sinai

Collaborators

[object Object]
[object Object]